Episode 169: Pancreatic Cancer Series, Pt. 4 – Metastatic Disease
This plays from the publisher's own server. We do not host a copy.
Description
This week, we continue our Pancreatic Cancer series with the setting where most of our patients live: metastatic disease. Using our case of a patient with newly diagnosed metastatic pancreatic cancer, we trace how first-line chemotherapy evolved from single-agent gemcitabine to FOLFIRINOX, gemcitabine/nab-paclitaxel, and NALIRIFOX, then work through how to pick a regimen for the patient in front of you, why germline and somatic testing belong at the first visit, what the POLO trial does and doesn't tell us about maintenance olaparib, and the story of the year: daraxonrasib, the RAS(ON) inhibitor that finally drugged the "undruggable" target in RASolute 302. We finish with second-line sequencing.
As always, if you haven't heard the earlier episodes in this series, including our introduction, approach to resectable disease, and approach to borderline and locally advanced disease, be sure to check those out first.
And listeners - stay tuned! We will follow up these conversations with our interviews with our surgery and radiation colleagues in upcoming episodes!
This episode is sponsored by Primum! As questions of oncology experts (including pancreatic cancer) free! To learn more and to sign up for your free account, visit Primum.co/fellows
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube
Back to The Fellow on Call: The Heme/Onc Podcast · Report a problem